PVLA
Palvella Therapeutics Inc.
$94.09
+$2.55(+2.79%)
65
Overall
40
Value
91
Tech
--
Quality
Market Cap
$937.64M
Volume
232.89K
52W Range
$11.17 - $101.94
Target Price
$113.75
Company Overview
| Mkt Cap | $937.64M | Price | $94.09 |
| Volume | 232.89K | Change | +2.79% |
| P/E Ratio | -53.8 | Open | $90.85 |
| Revenue | -- | Prev Close | $91.54 |
| Net Income | $-17.4M | 52W Range | $11.17 - $101.94 |
| Div Yield | N/A | Target | $113.75 |
| Overall | 65 | Value | 40 |
| Quality | -- | Technical | 91 |
No chart data available
About Palvella Therapeutics Inc.
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.
Latest News
Palvella Therapeutics (PVLA) Gets a Buy from LifeSci Capital
TipRanks Auto-Generated Intelligence Newsdesk•8 days ago
Chardan Capital Reaffirms Their Buy Rating on Palvella Therapeutics (PVLA)
TipRanks Auto-Generated Intelligence Newsdesk•11 days ago
Palvella Therapeutics (PVLA) Gets a Buy from Chardan Capital
TipRanks Auto-Generated Intelligence Newsdesk•17 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PVLA | $94.09 | +2.8% | 232.89K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Palvella Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW